Steroid 5-α reductase type 2 activity in biopsies from malignant and normal prostatic tissues

Clinica Chimica Acta

Volumn 391, Issue 1-2, 2008, Pages 36-40

  Oliveira, Osmar Luiz Magalhães ^a,b   Koff, Walter José ^a,b   Muraro, Francine ^b   Santos, Emanuel Burck ^a   Gomes Soares, Daniel Freitas ^a   Trindade, Vera Maria Treis ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Biopsies; Prostate cancer; PSA; Steroid 5 reductase

Indexed keywords

CARBON 14; PROSTATE SPECIFIC ANTIGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; INCUBATION TIME; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIOACTIVITY; THIN LAYER CHROMATOGRAPHY;

AGED; AGED, 80 AND OVER; BIOPSY; DIHYDROTESTOSTERONE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 41849140777     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.01.027     Document Type: Article

References (30)

1. Bjelfman C., Söderström T.G., Brekkan E., et al. Differential gene expression of steroid 5α-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 82 (1997) 2210-2214
2. Titus M.A., Gregory C.W., Ford III O.H., Schell M.J., Maygarden S.J., and Mohler J.L. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4365-4371
3. Thigpen A.E., Cala K.M., and Russell D.W. Characterization of Chinese hamster ovary cell lines expressing human steroid 5 α-reductase isozymes. J Biol Chem 268 (1993) 17404-17412
4. Imperato-McGinley J., Gautier T., Zirinsky K., et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metabol 75 (1992) 1022-1026
5. Isaacs J.T., Brendler C.B., and Walsh P.C. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin Endocrinol Metab 56 (1983) 139-146
6. Petrow V. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate 9 (1986) 343-361
7. McNeal J.E. Normal histology of the prostate. Am J Surg Pathol 12 (1988) 619-633
8. Söderström T.G., Bjelfman C., Brekkan E., et al. Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 86 (2001) 855-858
9. Thomas L.N., Lazier C.B., Gupta R., et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63 (2005) 231-239
10. Ross R.K., Bernstein L., Lobo R.A., et al. 5α-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339 (1992) 887-889
11. Fuganti P.E., Tobias-Machado M., Pinto M.A., Simardi L.H., and Wroclawski E.R. Twelve core prostate biopsy versus six systematic sextant biopsies. Braz J Urol 28 (2002) 207-213
12. Furuta S., Fukuda Y., Sugimoto T., et al. Pharmacodynamic analysis of steroid 5α-reductase inhibitory actions of Z-350 in rat prostate. Eur J Pharmacol 426 (2001) 105-111
13. Normington K., and Russell D.W. Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes. J Biol Chem 27 (1992) 19548-19554
14. Pratis K., O'Donnell L., Ooi G.T., McLachlan R.I., and Robertson D.M. Enzyme assay for 5α-reductase type 2 activity in the presence of 5α-reductase type 1 activity in rat testis. Steroid Biochem Mol Biol 75 (2000) 75-82
15. Hirosumi J., Nakayama O., Fagan T., et al. J. Steroid Biochem Mol Biol 4 (1995) 357-363
16. Lowry O.H., Rosebrough N.J., Farr A.L., and Randell R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
17. Kellof G.J., Lieberman R., Steele V.E., et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57 4 Suppl 1 (2001) 46-51
18. Bostwick D.G., Burke H.B., Wheeler T.M., et al. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl 19 (1994) 283-289
19. Civantos F., Soloway M.S., and Pinto J.E. Histopathological effects of androgen deprivation in prostatic câncer. Semin Urol Oncol 14 2 Suppl 2 (1996) 22-31
20. Hellerstedt B.A., and Pienta K.J. The current state of hormonal therapy for prostate cancer. Cancer J Clin 52 3 (2002) 154-179
21. Nakamura Y., Suzuki T., Nakabayashi M., et al. In situ androgen producing enzymes in human prostate cancer. Endocr-Relat Cancer 12 (2005) 101-107
22. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial. J Urol 172 (2004) 1314-1317
23. Torres J.M., Ruiz E., and Ortega E. Development of a quantitative RT-PCR method to study 5 alpha-reductase mRNA isozymes in rat prostate in different androgen status. Prostate 56 (2003) 74-79
24. Iehlé C., Radvanyi F., Medina S.G.D., et al. Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68 (1999) 189-195
25. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
26. Andriole G.L., Humphrey P., Ray P., et al. Effect of the dual 5 alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 172 (2004) 915-919
27. Presti J.C., Fair W.R., Andriole G., et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 148 (1992) 1201-1204
28. Brufsky A., Fonteine-Rothe P., Berlane K., et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49 (1997) 913-920
29. Cote R.J., Skinner E.C., Salem C.E., et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 78 (1998) 413-418
30. Shirakawa T., Okada H., Acharya B., et al. Messenger RNA levels and enzyme activities of 5 α-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 58 (2004) 33-40